Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Dynamic vehicle routing with time windows in theory and practice.

Yang Z, van Osta JP, van Veen B, van Krevelen R, van Klaveren R, Stam A, Kok J, Bäck T, Emmerich M.

Nat Comput. 2017;16(1):119-134. doi: 10.1007/s11047-016-9550-9. Epub 2016 Apr 9.

2.

Survivin Autoantibodies Are Not Elevated in Lung Cancer When Assayed Controlling for Specificity and Smoking Status.

Broodman I, VanDuijn MM, Stingl C, Dekker LJ, Germenis AE, de Koning HJ, van Klaveren RJ, Aerts JG, Lindemans J, Luider TM.

Cancer Immunol Res. 2016 Feb;4(2):165-72. doi: 10.1158/2326-6066.CIR-14-0176. Epub 2015 Dec 11.

3.

Stereotactic body radiation therapy for oligometastases to the lung: a phase 2 study.

Nuyttens JJ, van der Voort van Zyp NC, Verhoef C, Maat A, van Klaveren RJ, van der Holt B, Aerts J, Hoogeman M.

Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):337-43. doi: 10.1016/j.ijrobp.2014.10.021.

PMID:
25636758
4.

Towards a close computed tomography monitoring approach for screen detected subsolid pulmonary nodules?

Scholten ET, de Jong PA, de Hoop B, van Klaveren R, van Amelsvoort-van de Vorst S, Oudkerk M, Vliegenthart R, de Koning HJ, van der Aalst CM, Vernhout RM, Groen HJ, Lammers JW, van Ginneken B, Jacobs C, Mali WP, Horeweg N, Weenink C, Thunnissen E, Prokop M, Gietema HA.

Eur Respir J. 2015 Mar;45(3):765-73. doi: 10.1183/09031936.00005914. Epub 2014 Nov 27. Erratum in: Eur Respir J. 2015 May;45(5):1517.

5.

Peptides from the variable region of specific antibodies are shared among lung cancer patients.

de Costa D, Broodman I, Calame W, Stingl C, Dekker LJ, Vernhout RM, de Koning HJ, Hoogsteden HC, Sillevis Smitt PA, van Klaveren RJ, Luider TM, Vanduijn MM.

PLoS One. 2014 May 1;9(5):e96029. doi: 10.1371/journal.pone.0096029. eCollection 2014.

6.

Semi-automatic quantification of subsolid pulmonary nodules: comparison with manual measurements.

Scholten ET, de Hoop B, Jacobs C, van Amelsvoort-van de Vorst S, van Klaveren RJ, Oudkerk M, Vliegenthart R, de Koning HJ, van der Aalst CM, Mali WT, Gietema HA, Prokop M, van Ginneken B, de Jong PA.

PLoS One. 2013 Nov 21;8(11):e80249. doi: 10.1371/journal.pone.0080249. eCollection 2013.

7.

European randomized lung cancer screening trials: Post NLST.

Field JK, van Klaveren R, Pedersen JH, Pastorino U, Paci E, Becker N, Infante M, Oudkerk M, de Koning HJ; European Randomized Screening Trial Group.

J Surg Oncol. 2013 Oct;108(5):280-6. doi: 10.1002/jso.23383. Epub 2013 Jul 25.

PMID:
23893464
8.

Lung cancer screening CT-based prediction of cardiovascular events.

Mets OM, Vliegenthart R, Gondrie MJ, Viergever MA, Oudkerk M, de Koning HJ, Mali WP, Prokop M, van Klaveren RJ, van der Graaf Y, Buckens CF, Zanen P, Lammers JW, Groen HJ, Isgum I, de Jong PA.

JACC Cardiovasc Imaging. 2013 Aug;6(8):899-907. doi: 10.1016/j.jcmg.2013.02.008. Epub 2013 Jun 13.

9.

Non-solid lung nodules on low-dose computed tomography: comparison of detection rate between 3 visualization techniques.

Scholten ET, Mali WP, Prokop M, van Ginneken B, Glandorf R, van Klaveren R, Oudkerk M, de Jong PA.

Cancer Imaging. 2013 Apr 15;13:150-4. doi: 10.1102/1470-7330.2013.0016.

10.

Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.

Buikhuisen WA, Burgers JA, Vincent AD, Korse CM, van Klaveren RJ, Schramel FM, Pavlakis N, Nowak AK, Custers FL, Schouwink JH, Gans SJ, Groen HJ, Strankinga WF, Baas P.

Lancet Oncol. 2013 May;14(6):543-51. doi: 10.1016/S1470-2045(13)70125-6. Epub 2013 Apr 12.

PMID:
23583604
11.

Subphenotypes of mild-to-moderate COPD by factor and cluster analysis of pulmonary function, CT imaging and breathomics in a population-based survey.

Fens N, van Rossum AG, Zanen P, van Ginneken B, van Klaveren RJ, Zwinderman AH, Sterk PJ.

COPD. 2013 Jun;10(3):277-85. doi: 10.3109/15412555.2012.744388. Epub 2013 Mar 28.

PMID:
23536961
12.

Performance of computer-aided detection of pulmonary nodules in low-dose CT: comparison with double reading by nodule volume.

Zhao Y, de Bock GH, Vliegenthart R, van Klaveren RJ, Wang Y, Bogoni L, de Jong PA, Mali WP, van Ooijen PM, Oudkerk M.

Eur Radiol. 2012 Oct;22(10):2076-84. doi: 10.1007/s00330-012-2437-y. Epub 2012 Jul 20.

13.

Blinded and uniform cause of death verification in a lung cancer CT screening trial.

Horeweg N, van Klaveren RJ, Groen HJ, Lammers JW, Weenink C, Nackaerts K, Mali W, Oudkerk M, de Koning HJ.

Lung Cancer. 2012 Sep;77(3):522-5. doi: 10.1016/j.lungcan.2012.04.018. Epub 2012 May 22.

14.

Optical detection of preneoplastic lesions of the central airways.

van der Leest C, Amelink A, van Klaveren RJ, Hoogsteden HC, Sterenborg HJ, Aerts JG.

ISRN Oncol. 2012;2012:957835. doi: 10.5402/2012/957835. Epub 2012 Mar 22.

15.

Complications following lung surgery in the Dutch-Belgian randomized lung cancer screening trial.

Van't Westeinde SC, Horeweg N, De Leyn P, Groen HJ, Lammers JW, Weenink C, Nackaerts K, van Klaveren RJ.

Eur J Cardiothorac Surg. 2012 Sep;42(3):420-9. doi: 10.1093/ejcts/ezs081. Epub 2012 Apr 5.

PMID:
22491665
16.

Generalisability of the results of the Dutch-Belgian randomised controlled lung cancer CT screening trial (NELSON): does self-selection play a role?

van der Aalst CM, van Iersel CA, van Klaveren RJ, Frenken FJ, Fracheboud J, Otto SJ, de Jong PA, Oudkerk M, de Koning HJ.

Lung Cancer. 2012 Jul;77(1):51-7. doi: 10.1016/j.lungcan.2012.02.021. Epub 2012 Mar 27.

PMID:
22459203
17.

The role of conventional bronchoscopy in the workup of suspicious CT scan screen-detected pulmonary nodules.

van 't Westeinde SC, Horeweg N, Vernhout RM, Groen HJM, Lammers JJ, Weenink C, Nackaerts K, Oudkerk M, Mali W, Thunnissen FB, de Koning HJ, van Klaveren RJ.

Chest. 2012 Aug;142(2):377-384. doi: 10.1378/chest.11-2030.

PMID:
22302298
18.

Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumors.

Nuyttens JJ, van der Voort van Zyp NC, Praag J, Aluwini S, van Klaveren RJ, Verhoef C, Pattynama PM, Hoogeman MS.

Radiother Oncol. 2012 Mar;102(3):383-7. doi: 10.1016/j.radonc.2011.12.023. Epub 2012 Jan 20.

PMID:
22265734
19.

History of tuberculosis as an independent prognostic factor for lung cancer survival.

Heuvers ME, Aerts JG, Hegmans JP, Veltman JD, Uitterlinden AG, Ruiter R, Rodenburg EM, Hofman A, Bakker M, Hoogsteden HC, Stricker BH, van Klaveren RJ.

Lung Cancer. 2012 Jun;76(3):452-6. doi: 10.1016/j.lungcan.2011.12.008. Epub 2012 Jan 9.

PMID:
22226628
20.

Mass spectrometry analyses of κ and λ fractions result in increased number of complementarity-determining region identifications.

Broodman I, de Costa D, Stingl C, Dekker LJ, VanDuijn MM, Lindemans J, van Klaveren RJ, Luider TM.

Proteomics. 2012 Jan;12(2):183-91. doi: 10.1002/pmic.201100244. Epub 2011 Dec 20.

PMID:
22120973
21.

No benefit for consensus double reading at baseline screening for lung cancer with the use of semiautomated volumetry software.

Wang Y, van Klaveren RJ, de Bock GH, Zhao Y, Vernhout R, Leusveld A, Scholten E, Verschakelen J, Mali W, de Koning H, Oudkerk M.

Radiology. 2012 Jan;262(1):320-6. doi: 10.1148/radiol.11102289. Epub 2011 Nov 21.

PMID:
22106357
22.

Screening for emphysema via exhaled volatile organic compounds.

Cristescu SM, Gietema HA, Blanchet L, Kruitwagen CL, Munnik P, van Klaveren RJ, Lammers JW, Buydens L, Harren FJ, Zanen P.

J Breath Res. 2011 Dec;5(4):046009. doi: 10.1088/1752-7155/5/4/046009. Epub 2011 Nov 10.

PMID:
22071870
23.

The effectiveness of a computer-tailored smoking cessation intervention for participants in lung cancer screening: a randomised controlled trial.

van der Aalst CM, de Koning HJ, van den Bergh KA, Willemsen MC, van Klaveren RJ.

Lung Cancer. 2012 May;76(2):204-10. doi: 10.1016/j.lungcan.2011.10.006. Epub 2011 Nov 4.

PMID:
22054915
24.

Identification of chronic obstructive pulmonary disease in lung cancer screening computed tomographic scans.

Mets OM, Buckens CF, Zanen P, Isgum I, van Ginneken B, Prokop M, Gietema HA, Lammers JW, Vliegenthart R, Oudkerk M, van Klaveren RJ, de Koning HJ, Mali WP, de Jong PA.

JAMA. 2011 Oct 26;306(16):1775-81. doi: 10.1001/jama.2011.1531.

PMID:
22028353
25.

Lung cancer screening.

van Klaveren RJ.

Eur J Cancer. 2011 Sep;47 Suppl 3:S147-55. doi: 10.1016/S0959-8049(11)70158-7. Review. No abstract available.

PMID:
21943968
26.

Chairperson's introduction: The goal of cancer screening is to detect cancer when it is early and treatable, if not curable.

van Klaveren RJ.

Eur J Cancer. 2011 Sep;47 Suppl 3:S132. doi: 10.1016/S0959-8049(11)70156-3. No abstract available.

PMID:
21943966
27.

The role of the ¹⁸f-fluorodeoxyglucose-positron emission tomography scan in the Nederlands Leuvens Longkanker screenings Onderzoek lung cancer screening trial.

van't Westeinde SC, de Koning HJ, Thunnissen FB, Oudkerk M, Groen HJ, Lammers JW, Weenink C, Vernhout R, Nackaerts K, Mali W, van Klaveren RJ.

J Thorac Oncol. 2011 Oct;6(10):1704-12. doi: 10.1097/JTO.0b013e3182286d0b.

28.

A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03).

Gaafar RM, Surmont VF, Scagliotti GV, Van Klaveren RJ, Papamichael D, Welch JJ, Hasan B, Torri V, van Meerbeeck JP; EORTC Lung Cancer Group and the Italian Lung Cancer Project.

Eur J Cancer. 2011 Oct;47(15):2331-40. doi: 10.1016/j.ejca.2011.06.045. Epub 2011 Jul 28.

PMID:
21802939
29.

Ultrafast selective quantification of methotrexate in human plasma by high-throughput MALDI-isotope dilution mass spectrometry.

Meesters RJ, den Boer E, Mathot RA, de Jonge R, van Klaveren RJ, Lindemans J, Luider TM.

Bioanalysis. 2011 Jun;3(12):1369-78. doi: 10.4155/bio.11.113.

PMID:
21679031
30.

Association of the transfer coefficient of the lung for carbon monoxide with emphysema progression in male smokers.

Mohamed Hoesein FA, Zanen P, van Ginneken B, van Klaveren RJ, Lammers JW.

Eur Respir J. 2011 Nov;38(5):1012-8. doi: 10.1183/09031936.00050711. Epub 2011 May 12.

31.

CT-quantified emphysema in male heavy smokers: association with lung function decline.

Mohamed Hoesein FA, de Hoop B, Zanen P, Gietema H, Kruitwagen CL, van Ginneken B, Isgum I, Mol C, van Klaveren RJ, Dijkstra AE, Groen HJ, Boezen HM, Postma DS, Prokop M, Lammers JW.

Thorax. 2011 Sep;66(9):782-7. doi: 10.1136/thx.2010.145995. Epub 2011 Apr 7.

PMID:
21474499
32.

Lung cancer screening: what is the benefit and what do we do about it?

Mulshine JL, van Klaveren RJ.

Lung Cancer. 2011 Mar;71(3):247-8. doi: 10.1016/j.lungcan.2010.12.010. Epub 2011 Jan 31. No abstract available.

PMID:
21277040
33.

Screening and early detection of lung cancer.

Van't Westeinde SC, van Klaveren RJ.

Cancer J. 2011 Jan-Feb;17(1):3-10. doi: 10.1097/PPO.0b013e3182099319. Review.

PMID:
21263260
34.

Is CT screening for lung cancer ready for prime time?

van Klaveren RJ.

J Thorac Imaging. 2011 Feb;26(1):4-5. doi: 10.1097/RTI.0b013e31820badb3. No abstract available.

PMID:
21258223
35.

The impact of a lung cancer computed tomography screening result on smoking abstinence.

van der Aalst CM, van Klaveren RJ, van den Bergh KA, Willemsen MC, de Koning HJ.

Eur Respir J. 2011 Jun;37(6):1466-73. doi: 10.1183/09031936.00035410. Epub 2010 Dec 9. Erratum in: Eur Respir J. 2011 Aug;38(2):489-90.

36.

Long-term effects of lung cancer computed tomography screening on health-related quality of life: the NELSON trial.

van den Bergh KA, Essink-Bot ML, Borsboom GJ, Scholten ET, van Klaveren RJ, de Koning HJ.

Eur Respir J. 2011 Jul;38(1):154-61. doi: 10.1183/09031936.00123410. Epub 2010 Dec 9.

37.

A new ultrafast and high-throughput mass spectrometric approach for the therapeutic drug monitoring of the multi-targeted anti-folate pemetrexed in plasma from lung cancer patients.

Meesters RJ, Cornelissen R, van Klaveren RJ, de Jonge R, den Boer E, Lindemans J, Luider TM.

Anal Bioanal Chem. 2010 Dec;398(7-8):2943-8. doi: 10.1007/s00216-010-4192-8. Epub 2010 Sep 25.

38.

Does participation to screening unintentionally influence lifestyle behaviour and thus lifestyle-related morbidity?

van der Aalst CM, van Klaveren RJ, de Koning HJ.

Best Pract Res Clin Gastroenterol. 2010 Aug;24(4):465-78. doi: 10.1016/j.bpg.2010.06.001. Review.

PMID:
20833350
39.

Lung cancer screening and smoking abstinence: 2 year follow-up data from the Dutch-Belgian randomised controlled lung cancer screening trial.

van der Aalst CM, van den Bergh KA, Willemsen MC, de Koning HJ, van Klaveren RJ.

Thorax. 2010 Jul;65(7):600-5. doi: 10.1136/thx.2009.133751.

PMID:
20627916
40.

Informed decision making does not affect health-related quality of life in lung cancer screening (NELSON trial).

van den Bergh KA, Essink-Bot ML, van Klaveren RJ, de Koning HJ.

Eur J Cancer. 2010 Dec;46(18):3300-6. doi: 10.1016/j.ejca.2010.05.030. Epub 2010 Jun 26.

PMID:
20580546
41.

A randomized phase II study comparing two schedules of the 21-day regimen of gemcitabine and carboplatin in advanced non-small cell lung cancer.

Surmont V, Aerts JG, van Klaveren RJ, Tournoy K, Tan KY, Vernhout RM, Schmitz PI, Legrand C, Hoogsteden HC, van Meerbeeck JP.

Oncology. 2010;78(3-4):267-70. doi: 10.1159/000315733. Epub 2010 Jun 7.

PMID:
20523087
42.

Screening for lung cancer with digital chest radiography: sensitivity and number of secondary work-up CT examinations.

de Hoop B, Schaefer-Prokop C, Gietema HA, de Jong PA, van Ginneken B, van Klaveren RJ, Prokop M.

Radiology. 2010 May;255(2):629-37. doi: 10.1148/radiol.09091308.

PMID:
20413773
43.

Sequencing and quantifying IgG fragments and antigen-binding regions by mass spectrometry.

de Costa D, Broodman I, Vanduijn MM, Stingl C, Dekker LJ, Burgers PC, Hoogsteden HC, Sillevis Smitt PA, van Klaveren RJ, Luider TM.

J Proteome Res. 2010 Jun 4;9(6):2937-45. doi: 10.1021/pr901114w.

PMID:
20387908
44.

Pulmonary ground-glass nodules: increase in mass as an early indicator of growth.

de Hoop B, Gietema H, van de Vorst S, Murphy K, van Klaveren RJ, Prokop M.

Radiology. 2010 Apr;255(1):199-206. doi: 10.1148/radiol.09090571. Epub 2010 Feb 1.

PMID:
20123896
45.

Pemetrexed and cisplatin with concurrent radiotherapy for locally advanced non-small cell and limited disease small cell lung cancer: results from 2 phase I studies.

Surmont V, Smit EF, de Jonge M, Aerts JG, Nackaerts K, Vernhout R, Gras J, Van Wijk A, Phernambucq EC, van Meerbeeck JP, Senan S, Kraaij CJ, Chouaki N, Praag J, van Klaveren RJ.

Lung Cancer. 2010 Sep;69(3):302-6. doi: 10.1016/j.lungcan.2009.12.001. Epub 2010 Jan 22.

PMID:
20096951
46.

Stereotactic body radiotherapy using real-time tumor tracking in octogenarians with non-small cell lung cancer.

van der Voort van Zyp NC, van der Holt B, van Klaveren RJ, Pattynama P, Maat A, Nuyttens JJ.

Lung Cancer. 2010 Sep;69(3):296-301. doi: 10.1016/j.lungcan.2009.12.008. Epub 2010 Jan 8.

PMID:
20060195
47.

The 15q24/25 susceptibility variant for lung cancer and chronic obstructive pulmonary disease is associated with emphysema.

Lambrechts D, Buysschaert I, Zanen P, Coolen J, Lays N, Cuppens H, Groen HJ, Dewever W, van Klaveren RJ, Verschakelen J, Wijmenga C, Postma DS, Decramer M, Janssens W.

Am J Respir Crit Care Med. 2010 Mar 1;181(5):486-93. doi: 10.1164/rccm.200909-1364OC. Epub 2009 Dec 10.

PMID:
20007924
48.

Management of lung nodules detected by volume CT scanning.

van Klaveren RJ, Oudkerk M, Prokop M, Scholten ET, Nackaerts K, Vernhout R, van Iersel CA, van den Bergh KA, van 't Westeinde S, van der Aalst C, Thunnissen E, Xu DM, Wang Y, Zhao Y, Gietema HA, de Hoop BJ, Groen HJ, de Bock GH, van Ooijen P, Weenink C, Verschakelen J, Lammers JW, Timens W, Willebrand D, Vink A, Mali W, de Koning HJ.

N Engl J Med. 2009 Dec 3;361(23):2221-9. doi: 10.1056/NEJMoa0906085.

49.

Short-term health-related quality of life consequences in a lung cancer CT screening trial (NELSON).

van den Bergh KA, Essink-Bot ML, Borsboom GJ, Th Scholten E, Prokop M, de Koning HJ, van Klaveren RJ.

Br J Cancer. 2010 Jan 5;102(1):27-34. doi: 10.1038/sj.bjc.6605459. Epub 2009 Nov 24.

50.

Volumetric measurement of pulmonary nodules at low-dose chest CT: effect of reconstruction setting on measurement variability.

Wang Y, de Bock GH, van Klaveren RJ, van Ooyen P, Tukker W, Zhao Y, Dorrius MD, Proença RV, Post WJ, Oudkerk M.

Eur Radiol. 2010 May;20(5):1180-7. doi: 10.1007/s00330-009-1634-9. Epub 2009 Nov 18.

Supplemental Content

Loading ...
Support Center